Showing 3091-3100 of 3223 results for "".
- Kala Pharmaceuticals Announces the Launch of Inveltyshttps://modernod.com/news/kala-pharmaceuticals-announces-the-launch-of-inveltys-and-the-hiring-of-a-specialty-ophthalmology-sales-organization/2476217/Kala Pharmaceuticals announced the launch of Inveltys (loteprednol etabonate ophthalmic suspension) 1%, the first and only twice-daily ocular corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. Kala also announced the hiring of the specialty
- George A. Williams, MD, Begins Term as 2019 President of the American Academy of Ophthalmologyhttps://modernod.com/news/george-a-williams-md-begins-term-as-2019-president-of-the-american-academy-of-ophthalmology/2476229/George A. Williams, MD, today begins his term as the 123rd president of the American Academy of Ophthalmology. Dr. Williams, a retina specialist, was elected by the Academy’s community of 32,000 ophthalmologists in recognition of his scientific leadership and his deep commitment to advocati
- Ophthotech Announces the Addition of Calvin W. Roberts, MD, to Its Board of Directorshttps://modernod.com/news/ophthotech-announces-the-addition-of-ophthalmic-industry-leader-calvin-w-roberts-md-to-its-board-of-directors/2476231/Ophthotech Corporation announced the election of Calvin (Cal) W. Roberts, MD, Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies, and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, to its Board of Directors, effective as of Ja
- Lightmed Founder and Executive Chairman Gary Lee Reassumes CEO Rolehttps://modernod.com/news/lightmed-founder-and-executive-chairman-gary-lee-reassumes-ceo-role/2476234/Lightmed Corporation announced the reappointment of founder and Executive Chairman Gary Lee as Chief Executive Officer, effective immediately. Shlomo Alkalay has accomplished his CEO assignment and will return to his
- Ocular Therapeutix Announces Completion of Debt Refinancinghttps://modernod.com/news/ocular-therapeutix-announces-completion-of-debt-refinancing/2476236/Ocular Therapeutix announced that it has closed a refinancing of its existing debt by entering into a new $25 million term loan with MidCap Financial and Silicon Valley Bank. The 5-year term loan facility allows for an expansion of the company’s prior $18 million credit facility to $25 mil
- 2018 Best of Eyetubehttps://modernod.com/news/2018-best-of-eyetube/2476238/Cataract & Refractive Surgery Today (CRST) has compiled the best content of 2018 from Eyetube.net, the leading video resource for ophthalmologists. Below are descriptions of a few of the top videos. To view all of the videos and their descriptions, click
- AMD Monitoring Comes Home: The Promise of Innovative Remote Techhttps://modernod.com/news/amd-monitoring-comes-home-the-promise-of-innovative-remote-tech/2476239/Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, or the central part of the retina, which has the highest density of photoreceptors, allowing for high-resolution central visual acuity. An e
- Mount Sinai Recruits Internationally Recognized Ophthalmologists to Expand Leadershiphttps://modernod.com/news/mount-sinai-recruits-internationally-recognized-ophthalmologists-to-expand-leadership/2479609/Mount Sinai Health System announced the appointment of two new faculty members to expand leadership in the Department of Ophthalmology. Louis R. Pasquale, MD, FARVO, has been named Site Chair of Ophthalmology at The Mount Sinai Hospital and Mount Sinai Queens and will also serve as Vice Chair of
- Higher Eye Pressure After Anti-VEGF Therapy Needs More Attentionhttps://modernod.com/news/higher-eye-pressure-after-anti-vegf-therapy-needs-more-attention/2476255/The elevated IOP known to follow intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents may persist in certain patients, according to a report by the American Academy of Ophthalmology (AAO), as reported by Reuters
- Bausch Health to Purchase Majority of Synergy Pharmaceuticals’ Assets, Including Trulancehttps://modernod.com/news/bausch-health-to-purchase-majority-of-synergy-pharmaceuticals-assets-including-trulance/2479614/Bausch Health announced a deal to purchase nearly all of the assets of bankrupt drugmaker Synergy Pharmaceuticals for about $200 million in cash, with the transaction including the constipation treatment Trulance (plecanatide), according to FirstWord. Bausch Health CEO Joseph Papa noted that the